October 7th 2025
The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing options.
Gallus BioPharmaceuticals Uses ambr15 Micro Bioreactor to Develop Novel Antibodies and Biosimilars
April 30th 2014TAP Biosystems announced that Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.